ArticleThe Journal of infectious diseases2026
Genomic Surveillance Reveals Emergence and Spread of Macrolide-Resistant Mycoplasma pneumoniae in Australia During the 2023-2024 Epidemic.
Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
Abstract
backgroundThe resurgence of Mycoplasma pneumoniae, first reported in China in 2023, was attributed to waning postpandemic immunity with increases in macrolide-resistant M. pneumoniae (MRMP) (> 80%). In Australia, infections peaked in early 2024, particularly among children under 15 years. While MRMP remains low in Europe, North America, and Australia (< 5%), limited routine testing restricts understanding of resistance dynamics. As macrolides are first-line therapy in many settings, MRMP surveillance is essential for guiding empirical treatment.
methodsWe applied a capture-based targeted metagenomic sequencing (targeted next-generation sequencing [tNGS]) to polymerase chain reaction (PCR)-positive M. pneumoniae specimens (n = 356) from across Australia. This approach enabled whole-genome recovery and MRMP detection directly from clinical specimens, without culture. MRMP detections were benchmarked against PCR and data were analyzed to assess associations between resistance and health care utilization.
resultsThis is the first genomics-informed national study of M. pneumoniae in Australia. We recovered 124 high-quality genomes, revealing a genetically diverse population with cocirculation of P1 type 1 (69%) and type 2 (31%). MRMP was identified in 13% of genomes, all belonging to clades that prior to 2024 had only been reported in Asia (ST3 and ST14). MRMP cases were geographically widespread, suggesting importation and local transmission. Unlike reports from China, macrolide-susceptible clades (ST3, ST7, ST17, and ST20) predominated (87%) and were associated with significantly lower health care utilization compared to MRMP cases.
conclusionsOur findings demonstrate the utility of tNGS for genomic epidemiology and highlight the need for MRMP surveillance. Although macrolides remain effective in Australia, emerging MRMP strains require close monitoring to inform treatment guidelines and antimicrobial stewardship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.